# Mendelian randomization studies in atopic dermatitis: causal insights across omics layers

## TL;DR

This paper explores how Mendelian randomization helps uncover causal links in atopic dermatitis, offering insights for better treatments and precision medicine.

## Contribution

The paper highlights the use of multi-omic MR approaches to discover biomarkers and therapeutic targets in atopic dermatitis.

## Key findings

- MR studies show causal associations between AD and various comorbidities like neuropsychiatric and immune conditions.
- Multi-omic MR approaches enable therapeutic target discovery and drug repurposing opportunities.
- MR is advancing precision medicine by integrating causal inference across omics layers.

## Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease, shaped by genetic, immune and environmental factors. Even though this complex interaction has been thoroughly studied, uncovering causal relationships between specific exposures and AD remains challenging. Mendelian randomization (MR) has emerged as a powerful tool for establishing causal inferences between exposures and outcomes, using genome-wide association data. MR studies have provided evidence for potential causal associations between AD and a broad spectrum of traits and comorbidities, including neuropsychiatric, cardiometabolic, oncologic, immune-mediated conditions, as well as ophthalmologic and infectious complications. Moreover, multi-omic MR approaches have enabled biomarker and therapeutic target discovery, highlighting opportunities for screening refinement, drug repurposing, and precision medicine. By integrating causal inference tools within multiple omics layers, MR is reshaping our understanding of AD, accelerating progress toward precision medicine in immune-mediated diseases.